Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · see citing works

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 991 · see citing works

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · see citing works

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812 · see citing works

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 778 · see citing works

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778 · see citing works

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Zamagni, E., Patriarca, F. F., Nanni, C., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 533 · see citing works

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E. J., Alpe, T. L., Angtuaco, E., Walker, R. C., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 516 · see citing works

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

Varettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 488 · see citing works

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Rosiñol, L., Oriol, A., Teruel, A. I., Hernández‐Maraver, D., López‐Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486 · see citing works

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Dimopoulos, M. A., Terpos, E., Comenzo, R. L., Tosi, P., Beksaç, M., Sezer, O., Siegel, D. S. D., Lokhorst, H. M., Kumar, S. K., Rajkumar, S. V., et al. (2009) · Leukemia · doi:10.1038/leu.2009.89 · Cited by 479 · see citing works

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

Dimopoulos, M. A., Kyle, R. A., Fermand, J., Rajkumar, S. V., Miguel, J. F. S., Chanan-Khan, A. A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299529 · Cited by 450 · see citing works

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407 · see citing works

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Dimopoulos, M. A., Hillengaß, J., Usmani, S. Z., Zamagni, E., Lentzsch, S., Davies, F. E., Raje, N. S., Sezer, O., Zweegman, S., Shah, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9961 · Cited by 396 · see citing works

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Usmani, S. Z., Heuck, C. J., Mitchell, A., Szymonifka, J. D., Nair, B. P., Hoering, A., Alsayed, Y. M., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 395 · see citing works

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

Bladé, J., de Larrea, C. F., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 388 · see citing works

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Caers, J., Paiva, B., Zamagni, E., Leleu, X. P., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0549-1 · Cited by 338 · see citing works

Prospective Evaluation of Magnetic Resonance Imaging and [ 18 F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Moreau, P., Attal, M., Caillot, D., Macro, M., Karlin, L., Garderet, L., Facon, T. T. F., Benboubker, L., Escoffre‐Barbe, M., Stoppa, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2975 · Cited by 327 · see citing works

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

Sonneveld, P., Goldschmidt, H., Rosiñol, L., Bladé, J., Lahuerta, J. J., Cavo, M., Tacchetti, P., Zamagni, E., Attal, M., Lokhorst, H. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4626 · Cited by 248 · see citing works

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242 · see citing works

Extramedullary multiple myeloma

Bhutani, M., Foureau, D., Atrash, S., Voorhees, P. M., & Usmani, S. Z. (2019) · Leukemia · doi:10.1038/s41375-019-0660-0 · Cited by 233 · see citing works

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Short, K. D., Rajkumar, S. V., Larson, D. R., Buadi, F. K., Hayman, S. R., Dispenzieri, A. A., Gertz, M. A., Kumar, S. K., Mikhael, J. R., Roy, V., et al. (2011) · Leukemia · doi:10.1038/leu.2011.29 · Cited by 209 · see citing works

Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years

Bladé, J., Kyle, R. A., & Greipp, P. R. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.5191061.x · Cited by 202 · see citing works

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Usmani, S. Z., Mitchell, A., Waheed, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451690 · Cited by 202 · see citing works

Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.

Bladé, J., Lust, J. A., & Kyle, R. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2398 · Cited by 198 · see citing works

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma

Pellat‐Deceunynck, C., Barillé, S., Jégo, G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401211 · Cited by 195 · see citing works

How I treat extramedullary myeloma

Touzeau, C., & Moreau, P. (2015) · Blood · doi:10.1182/blood-2015-07-635383 · Cited by 190 · see citing works

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

Pour, L., Sevcikova, S., Grešlíková, H., Kupská, R., Májková, P., Zahradová, L., Sandecká, V., Adam, Z., Krejčí, M., Kuglík, P., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.094409 · Cited by 187 · see citing works

Myeloma as a model for the process of metastasis: implications for therapy

Ghobrial, I. M. (2012) · Blood · doi:10.1182/blood-2012-01-379024 · Cited by 185 · see citing works

Extramedullary lesions in multiple myeloma; review of literature and pathologic studies.

Dw, H., BENNETT, W. A., & Fj, H. (1952) · PubMed · Cited by 154 · see citing works

Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death

Moreau, P., Cavo, M., Sonneveld, P., Rosiñol, L., Attal, M., Pezzi, A., Goldschmidt, H., Lahuerta, J. J., Marit, G., Palumbo, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0329 · Cited by 153 · see citing works

Central nervous system myelomatosis: review of the literature

Nieuwenhuizen, L., & Biesma, D. H. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00956.x · Cited by 147 · see citing works

The role of imaging techniques in the management of multiple myeloma

Zamagni, E., & Cavo, M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12007 · Cited by 146 · see citing works

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Jurczyszyn, A. J., Grząśko, N., Gozzetti, A., Czepiel, J., Cerase, A., Hungria, V., Crusoé, E. D. Q., Dias, A. L. M. S., Vij, R., Fiala, M. A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24351 · Cited by 146 · see citing works

The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells

Yata, K., & Yaccoby, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403513 · Cited by 135 · see citing works

Extramedullary multiple myeloma escapes the effect of thalidomide.

Rosiñol, L., Cibeira, M. T., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Segarra, M., Cid, M. C., Filella, X., & Montserrat, E. (2004) · PubMed · Cited by 134 · see citing works

Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients

Gozzetti, A., Cerase, A., Lotti, F., Rossi, D., Palumbo, A., Petrucci, M. T., Patriarca, F. F., Nozzoli, C., Cavo, M., Offidani, M., et al. (2011) · Cancer · doi:10.1002/cncr.26447 · Cited by 134 · see citing works

Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions

Chang, H., Sloan, S., Li, D., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05199.x · Cited by 133 · see citing works

FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma

Lu, Y.-Y., Chen, J.-H., Lin, W., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31825b2071 · Cited by 132 · see citing works

18F‐fluoro‐deoxyglucose positron emission tomography in assessment of myeloma‐related bone disease: A systematic review

van Lammeren‐Venema, D., Regelink, J. C., Riphagen, I. I., et al. (2011) · Cancer · doi:10.1002/cncr.26467 · Cited by 132 · see citing works

Bortezomib: an effective agent in extramedullary disease in multiple myeloma

Rosiñol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O., Bladé, J., & Montserrat, E. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2462.x · Cited by 128 · see citing works

The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies

Mitsiades, C. S., McMillin, D. W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.007 · Cited by 125 · see citing works

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)

Nanni, C., Zamagni, E., Versari, A., Chauvie, S., Bianchi, A., Rensi, M., Bellò, M., Rambaldi, I., Gallamini, A., Patriarca, F. F., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3200-9 · Cited by 124 · see citing works

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

Chen, C. I., Masih‐Khan, E., Jiang, H., Rabea, A. M., Cserti-Gazdewich, C. M., Jimenez-Zepeda, V. H., Chu, C., Kukreti, V., Trudel, S., Tiedemann, R. E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12414 · Cited by 121 · see citing works

The impact of extramedullary disease at presentation on the outcome of myeloma

Wu, P., Davies, F. E., Boyd, K. D., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802657751 · Cited by 115 · see citing works

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Gagelmann, N., Eikema, D.-J., Iacobelli, S., Köster, L., Nahi, H., Stoppa, A., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.178434 · Cited by 114 · see citing works

Extravasation and homing mechanisms in multiple myeloma

Broek, I. V., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9108-4 · Cited by 108 · see citing works

Multiple Myeloma Invasion of the Central Nervous System

Schluterman, K. O., Fassas, A., Hemert, R. L. V., & Harik, S. I. (2004) · Archives of Neurology · doi:10.1001/archneur.61.9.1423 · Cited by 108 · see citing works

Multiple Myeloma: Lesions of the Extra-osseous Hematopoietic System

Churg, J., & Gordon, A. J. (1950) · American Journal of Clinical Pathology · doi:10.1093/ajcp/20.10.934 · Cited by 105 · see citing works

Cytogenetics of extramedullary manifestations in multiple myeloma

Billecke, L., Penas, E. M. M., May, A. M., Engelhardt, M. M., Nagler, A., Leiba, M., Schiby, G., Kröger, N. M., Zustin, J., Marx, A. H., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12223 · Cited by 100 · see citing works

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

Rasche, L., Bernard, C., Topp, M. S., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H., & Knop, S. T. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1414-5 · Cited by 99 · see citing works

Geographic pathology of thyroid carcinoma

Cuello, C., Correa, P., & Eisenberg, H. (1969) · Cancer · doi:10.1002/1097-0142(196901)23:1 · Cited by 94 · see citing works

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

Weinstock, M. A., Aljawai, Y. M., Morgan, E. A., Laubach, J. P., Gannon, M., Roccaro, A. M., Varga, C., Mitsiades, C. S., Paba‐Prada, C. E., Schlossman, R. L., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13383 · Cited by 94 · see citing works

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Smith, E. L., Mailankody, S., Stæhr, M., Wang, X., Sénéchal, B., Purdon, T. J., Daniyan, A. F., Geyer, M. B., Goldberg, A. D., Mead, E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0551 · Cited by 94 · see citing works

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Beksaç, M., Seval, G. C., Kanellias, N., Coriu, D., Rosiñol, L., Özet, G., Goranova-Marinova, V. S., Ünal, A., Bila, J., Özsan, H., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219295 · Cited by 93 · see citing works

State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings

Mesguich, C., Fardanesh, R., Tanenbaum, L. N., et al. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.09.012 · Cited by 91 · see citing works

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

Pérez‐Simón, J. A., Sureda, A., Fernández‐Avilés, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404085 · Cited by 91 · see citing works

Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry

Alegre, A. M., Granda, A., Martínez Chamorro, C., Díaz Mediavilla, J., Martínez, R., García Laraña, J., Lahuerta, J. J., Sureda, A. M., Bladé, J., de la Rubia, J., et al. (2002) · PubMed · doi:10.5281/zenodo.11276358 · Cited by 89 · see citing works

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 85 · see citing works

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

Varga, C., Xie, W., Laubach, J. P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13382 · Cited by 83 · see citing works

Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features

Fassas, A., Ward, S. M., Muwalla, F., Hemert, R. L. V., Schluterman, K. O., Harik, S. I., & Tricot, G. J. K. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001597964 · Cited by 82 · see citing works

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Richardson, P. G. G., Zimmerman, T. M., Hofmeister, C. C., Talpaz, M., Chanan-Khan, A. A., Kaufman, J. L., Laubach, J. P., Chauhan, D., Jakubowiak, A. J., Reich, S. D., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686378 · Cited by 79 · see citing works

Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome

Zeiser, R., Deschler-Baier, B., Bertz, H., Finke, J., & Engelhardt, M. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704713 · Cited by 76 · see citing works

Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases

Deng, S., Xu, Y., An, G., Sui, W., Zou, D., Zhao, Y., Qi, J., Li, F., Hao, M., & Qiu, L. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.013 · Cited by 70 · see citing works

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff, S., Hjorth, M., Turesson, I., Westin, J., Gimsing, P., Wislöff, F., Ahlberg, L., Carlson, K. E., Christiansen, I., Dahl, I. M. S., et al. (2006) · PubMed · Cited by 66 · see citing works

Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.

Patriarca, F. F., Prosdocimo, S., Tomadini, V., Vasciaveo, A., Bruno, B., & Fanin, R. (2005) · PubMed · Cited by 65 · see citing works

Marizomib for central nervous system‐multiple myeloma

Badros, A. Z., Singh, Z. N., Dhakal, B., Kwok, Y., MacLaren, A., Richardson, P. G. G., Trikha, M., & Hari, P. (2017) · British Journal of Haematology · doi:10.1111/bjh.14498 · Cited by 64 · see citing works

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Montefusco, V., Gay, F., Spada, S., Paoli, L. D., Raimondo, F. D., Ribolla, R., Musolino, C., Patriarca, F. F., Musto, P., Galieni, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219139 · Cited by 64 · see citing works

Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma

Avigdor, A., Raanani, P., Levi, I., Hardan, I., & Ben‐Bassat, I. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099330 · Cited by 60 · see citing works

p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma

Sheth, N., Yeung, J., & Chang, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.010 · Cited by 59 · see citing works

Cytogenetics in multiple myeloma patients progressing into extramedullary disease

Bešše, L., Sedlaříková, L., Grešlíková, H., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12688 · Cited by 55 · see citing works

The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system

Chang, H., Bartlett, E. S., Patterson, B. J., Chen, C. I., & Yi, Q. L. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05493.x · Cited by 54 · see citing works

P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

López‐Anglada, L., Gutierrez, N. C., Garcı́a, J. L., Mateos, M., Flores, T., & Miguel, J. F. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01399.x · Cited by 54 · see citing works

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

Katodritou, E., Terpos, E., Kastritis, E., Delimpasis, S., Symeonidis, A. S., Repousis, P., Kyrtsonis, M., Vadikolia, C., Michalis, E., Polychronidou, G., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2484-y · Cited by 54 · see citing works

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome

Minnema, M. C., van de Donk, N. W. C. J., Zweegman, S., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705982 · Cited by 53 · see citing works

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Cavo, M., Goldschmidt, H., Rosiñol, L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112899 · Cited by 52 · see citing works

The possible role of burden of therapy on the risk of myeloma extramedullary spread

Mangiacavalli, S., Pompa, A., Ferretti, V. V., Klersy, C., Cocito, F., Varettoni, M., Cartia, C. S., Cazzola, M., & Corso, A. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2847-z · Cited by 48 · see citing works

Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma

Lee, S., Kim, J. H., Jeon, Y., Yoon, J., Shin, S., Eom, K., Kim, Y., Kim, H., Lee, S., Cho, S., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2216-8 · Cited by 46 · see citing works

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Katodritou, E., Gastari, V., Verrou, E., Hadjiaggelidou, C., Varthaliti, M., Georgiadou, S., Laschos, K., Xirou, P., Yiannaki, E. E., Constantinou, N., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.036 · Cited by 46 · see citing works

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Zhou, X., Flüchter, P., Nickel, K., Meckel, K., Messerschmidt, J., Böckle, D., Knorz, S., Steinhardt, M., Krummenast, F., Danhof, S., et al. (2020) · Cancers · doi:10.3390/cancers12041035 · Cited by 44 · see citing works

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Jurczyszyn, A. J., Olszewska‐Szopa, M., Hungria, V. T. D. M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1128542 · Cited by 42 · see citing works

Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma

Černý, J., Fadare, O., Hutchinson, L., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01087.x · Cited by 41 · see citing works

Myelomatous meningitis

Chamberlain, M. C., & Glantz, M. (2008) · Cancer · doi:10.1002/cncr.23330 · Cited by 41 · see citing works

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

Muchtar, E., Gatt, M. E., Rouvio, O., Ganzel, C., Chubar, E., Suriu, C., Tadmor, T., Shevetz, O., Lavi, N., Shochat, T., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13799 · Cited by 40 · see citing works

Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma

de Larrea, C. F., Jiménez, R., Rosiñol, L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.150 · Cited by 37 · see citing works

The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma

Rasche, L., Strifler, S., Duell, J., Rosenwald, A., Buck, A. K., Maeder, U., Einsele, H., & Knop, S. T. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2023-2 · Cited by 35 · see citing works

Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant

Rosenblum, M. D., Bredeson, C., Chang, C., et al. (2003) · American Journal of Hematology · doi:10.1002/ajh.10296 · Cited by 34 · see citing works

Hematogenous extramedullary relapse in multiple myeloma ‐ a multicenter retrospective study in 127 patients

Avivi, I. M., Cohen, Y. C., Suska, A., Shragai, T., Mikala, G., Garderet, L., Gueye, M. S., Glickman, S., Jayabalan, D. S., Niesvizky, R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25579 · Cited by 34 · see citing works

The Arkansas approach to therapy of patients with multiple myeloma

Barlogie, B., Anaissie, E. J., van Rhee, F., Pineda‐Roman, M., Zangari, M., Shaughnessy, J. D., Epstein, J., & Crowley, J. J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.005 · Cited by 33 · see citing works

Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

Papanikolaou, X. D., Repousis, P., Τζένου, Τ., Maltezas, D., Kotsopoulou, M., Megalakaki, K., Angelopoulou, M. K., Dimitrakoloulou, E., Koulieris, E., Bartzis, V., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746683 · Cited by 33 · see citing works

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Jullien, M., Trudel, S., Tessoulin, B., Mahé, B., Dubruille, V., Blin, N., Gastinne, T., Bonnet, A., Lok, A., Lebourgeois, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03655-5 · Cited by 33 · see citing works

Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

Paubelle, É., Coppo, P., Garderet, L., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403855 · Cited by 32 · see citing works

Extensive soft‐tissue involvement by plasmablastic myeloma arising from displaced humeral fractures

de Larrea, C. F., Rosiñol, L., Cibeira, M. T., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01504.x · Cited by 27 · see citing works

Extramedullary disease in multiple myeloma in the era of novel agents

Bladé, J., de Larrea, C. F., & Rosiñol, L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13384 · Cited by 26 · see citing works

Lack of response to thalidomide in plasmacytomas

Myers, B., Grimley, C., Crouch, D. J. M., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.0115_1cr-6.x · Cited by 26 · see citing works

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Zamagni, E., Nanni, C., Dozza, L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111321 · Cited by 24 · see citing works

Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma

Jiménez‐Segura, R., Granell, M., Gironella, M., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13217 · Cited by 24 · see citing works

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT‐PACE

Srikanth, M., Davies, F. E., Wu, P., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01131.x · Cited by 22 · see citing works

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Yee, A. J., Huff, C. A., Chari, A., et al. (2019) · Blood · doi:10.1182/blood-2019-129038 · Cited by 22 · see citing works

Leptomeningeal Myelomatosis: A Rare but Devastating Manifestation of Multiple Myeloma Diagnosed Using Cytology, Flow Cytometry, and Fluorescent in situ Hybridization

Bommer, M., Kull, M., Teleanu, V., Schwarzwälder, P., Feuring‐Buske, M., Kroenke, J., Bunjes, D. W., & Langer, C. (2018) · Acta Haematologica · doi:10.1159/000489484 · Cited by 20 · see citing works

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.

Billecke, L., Penas, E. M. M., May, A. M., et al. (2012) · PubMed · Cited by 19 · see citing works

Multiple myeloma invasion of the central nervous system

Marjanović, S., Mijusković, Z., Stamatović, D., Madjaru, L., Ralic, T., Trimčev, J., Stojanović, J., & Radović, V. (2012) · Vojnosanitetski pregled · doi:10.2298/vsp1202209m · Cited by 17 · see citing works

Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors

Anagnostopoulos, A., Gika, D., Hamilos, G., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001733772 · Cited by 17 · see citing works

Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity?

Rosiñol, L., de Larrea, C. F., & Bladé, J. (2014) · Acta Haematologica · doi:10.1159/000354833 · Cited by 16 · see citing works

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution

Rosiñol, L., Jiménez, R., Rovira, M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.320 · Cited by 14 · see citing works

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

Vincent, L., Céballos, P., Plassot, C., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.48 · Cited by 12 · see citing works

Positron Emission Tomography With Computed Tomography–Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma

Zamagni, E., Nanni, C., Tacchetti, P., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.014 · Cited by 10 · see citing works

Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience

Bladé, J., Knop, S. T., Cohen, A. D., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3460.3460 · Cited by 9 · see citing works

Extramedullary multiple myeloma: extraosseous relapse is extra “bad news,” but why?

Moreau, P., & Polliack, A. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.753451 · Cited by 6 · see citing works

Extramedullary Plasmacytoma Over the scar from Long-lasting Past Surgery as Presenting Feature of Multiple Myeloma

Moreno, D. F., Setoaín, X., Bladé, J., et al. (2020) · Archives of Clinical and Biomedical Research · doi:10.26502/acbr.50170142 · Cited by 5 · see citing works

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis

Beksaç, M. (2020) · 62nd ASH Annual Meeting and Exposition · Cited by 4 · see citing works

Plasmacytomas in Multiple Myeloma: 45-Years Experience from a Single Institution

Rosiñol, L., Jiménez, R., Cibeira, M. T., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.03.194 · Cited by 3 · see citing works

Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population

Richardson, P. G. G., Mateos, M., Rodríguez‐Otero, P., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.582 · Cited by 3 · see citing works

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works

Extramedullary disease in multiple myeloma: a systematic literature review

Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319 · see citing works

Novel insights into the mechanism of action of lenalidomide

Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 19 · see citing works

Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies

Dou, A., & Fang, J. (2020) · Journal of Cellular Immunology · doi:10.33696/immunology.2.049 · Cited by 5 · see citing works

Lenalidomide-induced severe hepatotoxicity

Hussain, S., Browne, R., Chen, J. Y., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097758 · Cited by 32 · see citing works

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

Bartlett, J. B., Tozer, A., Stirling, D., & Zeldis, J. B. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602774 · Cited by 70 · see citing works

Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database

Olivier, P., Teisseyre, A.-C., & Montastruc, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0733-2 · Cited by 7 · see citing works